Methods of adjustment of antipsychotic treatment of the needs of the individual patients with schizophrenia

被引：0
作者：
Potanin, S. S. [1 ]
Burminsky, D. S. [1 ]
Morozova, M. A. [1 ]
机构：
[1] Russian Acad Med Sci, Mental Hlth Res Ctr, Moscow 109801, Russia
来源：
ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA | 2013年 / 113卷 / 10期
关键词：
schizophrenia; individualization of antipsychotic treatment; pharmacokinetic parameters; selection of antipsychotic drug; TREATMENT-RESISTANT SCHIZOPHRENIA; CLINICALLY IMPORTANT DIFFERENCES; COMBINED PHENOTYPIC ASSESSMENT; RANDOMIZED CONTROLLED-TRIAL; DRUG-METABOLIZING-ENZYMES; QUALITY-OF-LIFE; 1A2; CYP1A2; GENE; CYTOCHROME-P450; MONOZYGOTIC TWINS; ATYPICAL ANTIPSYCHOTICS;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：80 / 87
页数：8
相关论文
共 123 条
[11]   Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research [J].
Arranz, M. J. ;
de Leon, J. .
MOLECULAR PSYCHIATRY, 2007, 12 (08) :707-747
[12]   Pharmacogenetics in Psychiatry: Are We Ready for Widespread Clinical Use? [J].
Arranz, Maria J. ;
Kapur, Shitij .
SCHIZOPHRENIA BULLETIN, 2008, 34 (06) :1130-1144
[13]  
Arranz Maria J, 2011, Expert Rev Clin Pharmacol, V4, P389, DOI 10.1586/ecp.11.16
[14]  
BABUSHKINA EI, 2011, AVTOREF KAND MED NAU
[15]  
Bachmann CJ, 2008, THER DRUG MONIT, V30, P462, DOI 10.1097/FTD.0b013e318178e18d
[16]   Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: Reappraisal of interindividual variability factors [J].
Balant-Gorgia, AE ;
Gex-Fabry, M ;
Genet, C ;
Balant, LP .
THERAPEUTIC DRUG MONITORING, 1999, 21 (01) :105-115
[17]   Pharmacogenomics in schizophrenia: the quest for individualized therapy [J].
Basile, VS ;
Masellis, M ;
Potkin, SG ;
Kennedy, JL .
HUMAN MOLECULAR GENETICS, 2002, 11 (20) :2517-2530
[18]   A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene:: association with tardive dyskinesia in schizophrenia [J].
Basile, VS ;
Özdemir, V ;
Masellis, M ;
Walker, ML ;
Heltzer, HY ;
Lieberman, JA ;
Potkin, SG ;
Alva, G ;
Kalow, W ;
Macciardi, FM ;
Kennedy, JL .
MOLECULAR PSYCHIATRY, 2000, 5 (04) :410-417
[19]   The AGNP-TDM expert group consensus guidelines:: Therapeutic Drug Monitoring in psychiatry [J].
Baumann, P ;
Hiemke, C ;
Ulrich, S ;
Eckermann, G ;
Gaertner, I ;
Gerlach, M ;
Kuss, HJ ;
Laux, G ;
Müller-Oerlinghausen, B ;
Rao, ML ;
Riederer, P ;
Zernig, G .
PHARMACOPSYCHIATRY, 2004, 37 (06) :243-265
[20]  
Bitter I, 2003, PHARMACOPSYCHIATRY, V36, P143
12345678910